JP2021528368A5 - - Google Patents

Info

Publication number
JP2021528368A5
JP2021528368A5 JP2020562120A JP2020562120A JP2021528368A5 JP 2021528368 A5 JP2021528368 A5 JP 2021528368A5 JP 2020562120 A JP2020562120 A JP 2020562120A JP 2020562120 A JP2020562120 A JP 2020562120A JP 2021528368 A5 JP2021528368 A5 JP 2021528368A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
heterocyclyl
heteroaryl
sulfo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020562120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528368A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/031885 external-priority patent/WO2019217933A1/en
Publication of JP2021528368A publication Critical patent/JP2021528368A/ja
Publication of JP2021528368A5 publication Critical patent/JP2021528368A5/ja
Priority to JP2024022691A priority Critical patent/JP2024056937A/ja
Pending legal-status Critical Current

Links

JP2020562120A 2018-05-10 2019-05-10 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法 Pending JP2021528368A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024022691A JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669926P 2018-05-10 2018-05-10
US62/669,926 2018-05-10
PCT/US2019/031885 WO2019217933A1 (en) 2018-05-10 2019-05-10 Inhibitors of the ras oncoprotein, methods of making and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024022691A Division JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Publications (2)

Publication Number Publication Date
JP2021528368A JP2021528368A (ja) 2021-10-21
JP2021528368A5 true JP2021528368A5 (enExample) 2022-05-17

Family

ID=68467113

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562120A Pending JP2021528368A (ja) 2018-05-10 2019-05-10 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法
JP2024022691A Pending JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024022691A Pending JP2024056937A (ja) 2018-05-10 2024-02-19 Ras腫瘍性タンパク質の阻害剤、その作製方法及びその使用方法

Country Status (10)

Country Link
US (1) US12582660B2 (enExample)
EP (1) EP3790541B1 (enExample)
JP (2) JP2021528368A (enExample)
KR (1) KR20210009331A (enExample)
CN (1) CN112312901B (enExample)
AU (1) AU2019265011B2 (enExample)
CA (1) CA3099148A1 (enExample)
IL (1) IL278596B2 (enExample)
MX (1) MX2020011991A (enExample)
WO (1) WO2019217933A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020011991A (es) 2018-05-10 2021-04-12 Univ Louisville Res Found Inc Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
US20250195521A1 (en) 2020-09-03 2025-06-19 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60233051A (ja) 1984-05-04 1985-11-19 Daicel Chem Ind Ltd 2−クロル−5−ニトロベンゼンスルホンアミドの製造方法
US4944796A (en) * 1988-11-14 1990-07-31 Ici Americas Inc. Certain 2-(disubstituted amino) acetanilide herbicides
EP1086081A1 (en) * 1998-06-09 2001-03-28 Nortran Pharmaceuticals Inc. Quarternary ammonium compounds as anti-tussive agents
WO2008070831A2 (en) * 2006-12-07 2008-06-12 Xavier University Of Louisiana Bisbenzamidines and bisbenzamidoximes for the treatment of human african trypanosomiasis
US7951806B2 (en) * 2007-07-25 2011-05-31 Renascience Co., Ltd. Plasminogen activator inhibitor-1 inhibitor
FR2925495B1 (fr) * 2007-12-21 2010-09-10 Pf Medicament Derives dimeriques d'artemisinine et application en therapie anticancereuse
GB0808282D0 (en) 2008-05-07 2008-06-11 Medical Res Council Compounds for use in stabilizing p53 mutants
CN101919842A (zh) * 2009-06-11 2010-12-22 复旦大学 一种苯丙噻吩衍生物在制备抗肿瘤药物中的应用
US8557980B2 (en) 2010-02-18 2013-10-15 The Board Of Trustees Of The University Of Illinois Methods for forming protected organoboronic acids
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス,インコーポレイテッド K−ras変異を有する癌の治療
KR20120048223A (ko) 2010-11-05 2012-05-15 주식회사 이큐스앤자루 2-페닐-4-[3-(치환된-설포닐)아닐리노]퀴나졸린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 c형 간염의 예방 또는 치료용 약학적 조성물
GB201020397D0 (en) * 2010-12-02 2011-01-12 Univ Nottingham Compounds
EP2759533B1 (en) * 2011-09-22 2017-08-02 Takeda Pharmaceutical Company Limited Condensed heterocyclic compound
WO2014037726A1 (en) * 2012-09-06 2014-03-13 Verona Pharma Plc Liquid pharmaceutical compositions
ES2491390B1 (es) * 2013-02-04 2015-06-22 Universidad Complutense De Madrid Nuevos inhibidores de la enzima isoprenilcisteina carboximetiltransferasa (icmt)
RU2015148359A (ru) 2013-04-12 2017-05-15 Асана Биосайенсис, Ллк Хиназолины и азахиназолины - двойные ингибиторы путей ras/raf/mek/erk и pi3k/akt/pten/mtor
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20160168108A1 (en) * 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
WO2017161144A1 (en) 2016-03-16 2017-09-21 Endocyte, Inc. Carbonic anhydrase ix inhibitor conjugates and uses thereof
MX2020011991A (es) 2018-05-10 2021-04-12 Univ Louisville Res Found Inc Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
AU2009210655B2 (en) Treatment of bladder diseases with a TLR7 activator
RU2672575C2 (ru) Лечение рака головного мозга
ES2360125T3 (es) Formulación farmacéutica de decitabina.
JP2012529486A5 (enExample)
JP2014132009A5 (enExample)
JP2021528368A5 (enExample)
CN111035640B (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途
JP2019517587A5 (enExample)
JP6462147B2 (ja) Hsp90阻害ペプチド結合体及びその腫瘍治療における応用
CN107405404A (zh) 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
CN108602761A (zh) 四环素类的盐
EP4442321A3 (en) Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
HRP20191019T1 (hr) Kombinacijska terapija konjugatom protutijela i lijeka anti-her2 i inhibitorom bcl-2
JP2021534160A5 (enExample)
JP2020510075A5 (enExample)
JP2023553253A5 (enExample)
JP2012525411A5 (enExample)
RU2020131402A (ru) 4-метилдигидропиримидиноновые соединения и их применение в фармацевтике
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JP2014530204A5 (enExample)
CN1181819C (zh) 使用五氟苯磺酰胺的综合疗法
RU2018114457A (ru) Лечение syd985 пациентов с t-dm1 рефрактерным раком
JP2007530692A (ja) 6−メルカプトプリンの改良された製剤
EP2394642A1 (en) 5-ALA ester formulations and use thereof
RU2010118458A (ru) Производное изоксазола для лечения рака